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Abstract
Despite the productivity of basic cancer research, cancer continues to be a health burden to society because this research has 
not yielded corresponding clinical applications. Many proposed solutions to this dilemma have revolved around implement-
ing organizational and policy changes related to cancer research. Here I argue for a different solution: a new conceptualiza-
tion of causation in cancer. Neither the standard molecular biomarker approaches nor evolutionary biology approaches to 
cancer fully capture its complex causal dynamics, even when considered jointly. These approaches map on to Ernst Mayr’s 
proximate–ultimate distinction, which is an inadequate conceptualization of causation in biological systems and makes it 
difficult to connect developmental and evolutionary viewpoints. I propose looking to evolutionary developmental biology 
(EvoDevo) to overcome the distinction and integrate the proximate and ultimate causal frameworks. I use the concepts of 
modularity and evolvability to show how an EvoDevo perspective can be manifested in cancer translational research. This 
perspective on causation in cancer is better suited for integrating the complexity of current empirical results and can facilitate 
novel developments in the investigation and clinical treatment of cancer.
Keywords Biomarker · Cancer · Causation · Evolutionary developmental biology · Evolutionary medicine · Evolvability · 
Modularity · Proximate–ultimate
Introduction
Cancer research has made tremendous strides in recent dec-
ades, but it has yet to make the progress that we need it 
to. That is, numerous cancer-related reports are published 
each week, yet the rate at which discoveries are translated 
into effective clinical applications is low. Various parties 
have pointed to different reasons for this situation, includ-
ing funding and institutional barriers to research, as well as 
a conservative system that is fairly unsupportive of physi-
cians deviating from the norm. However, translation failure 
rates remained high despite a twofold increase in the US 
National Institutes of Health (NIH) budget between 1998 
and 2003 (Sarewitz 2013). The NIH, the Canadian Institutes 
of Health Research (CIHR), and other funding organizations 
have recently emphasized translational research: an endeavor 
specifically focused on translating the knowledge gained at 
the bench into clinical applications. Much of the attention 
in translational research has been devoted to organizational 
and policy changes that remove barriers to clinical trials, 
redesigning physician-scientist (MD/PhD) programs, and 
facilitating programs that encourage the formation of aca-
demic centers for interdisciplinary clinical and translational 
research which include members from basic research, bio-
medical research, industry, and practicing physicians, among 
others (e.g., the Clinical Translational Science Awards 
consortium through the NIH). However, less attention has 
been paid to whether the core research strategies used in 
translational research are adequate for the generation of 
desired clinical applications. It is assumed that prevailing 
approaches and frameworks will translate into clinical appli-
cations eventually, given enough time and the right combina-
tion of researchers. But this is a bad assumption; attending 
to institutional structure and research organization alone will 
not be sufficient. Cancer translational research needs a more 
radical solution.
I am not the first to recognize this, nor the first to sug-
gest a solution to this problem. Evolutionary and ecological 
approaches to cancer research emerged in response to the 
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lack of clinical applications from the basic biology discov-
eries (Wodarz 2006; Greaves and Maley 2012; see more 
below), and the parallels between cancers and ecosystems 
continue to be elucidated (Merlo et al. 2006; Kareva 2015). 
Physicists and mathematicians were recruited by the US 
National Cancer Institute to ask questions about cancer in 
new ways, including using their mathematical and compu-
tational skills to model and investigate virtual cancer sys-
tems (Michor et al. 2011; Agus and Michor 2012; Kuhn and 
Nagahara 2013). Philosophers also have sought to explain 
and make sense of cancers in novel ways (Bertolaso 2016), 
such as through multilevel selection (Lean and Plutynski 
2015) or cancer stem cell theory (Laplane 2016). Although 
these suggestions have led to valuable research programs, 
they miss a key issue at the root of the difficulties facing 
cancer translational research: the conceptualization of cau-
sation in cancer.
The central thesis of this article is that cancer transla-
tional research needs a new perspective on causation. In 
the next section, I review two predominant approaches to 
investigating cancer (the molecular biomarker approach 
and the evolutionary biology approach), and dissect their 
causal frameworks. Then in the following section, I argue 
that the frameworks are insufficient as they appear to map 
on to Ernst Mayr’s proximate–ultimate distinction, which is 
an inadequate conceptualization of causation in biological 
systems. In the fourth section, I suggest that this problem can 
be solved by looking at evolutionary developmental biology, 
which is an integration of ultimate causes (from evolution-
ary biology) and proximate causes (from developmental 
biology). I draw on discussions around major concepts in 
evolutionary developmental biology, specifically modularity 
and evolvability, and apply those concepts to cancer trans-
lational research. I make some concluding statements in the 
last section.
Before proceeding, I want to make explicit how I under-
stand the notions of “causation” and “causality.” I use the 
terms “causality,” “causes,” and “causation” nonoperation-
ally. That is, my goal is not to quantify causes or causal 
input, nor is it to identify the main cause(s) of cancer. Here, 
I want to suggest a novel conceptualization of how various 
causes are related. Once we are satisfied with the conceptu-
alization of causation, the next step is to operationalize that 
conceptualization for the detection of causes. However, this 
step is outside the scope of this article.
Predominant Approaches and Frameworks 
for Investigating Cancer
Molecular Biomarker Approach
Biomedical research has become increasingly molecular 
with the availability of technologies such as whole genome 
sequencing. The promise has been that a better understand-
ing of molecular mechanisms will make targeted clinical 
interventions possible. These interventions modify or cor-
rect abnormalities in particular individuals while minimizing 
side effects that come with traditional blanket treatments 
such as chemotherapy. The focus on targeted interventions in 
individuals has fueled the rise of precision medicine1 (Col-
lins and Varmus 2015). One version that has become wide-
spread is based on sequencing the genomes of individuals. 
The goals for this project are to develop and identify drugs 
that will be most effective based on the patient’s specific 
genomic composition. Because genomes can be sequenced, 
scanned, and compared quickly and (relatively) inexpen-
sively, researchers are especially interested in identifying 
variants that are biological markers of diseases (biomark-
ers). These variants are supposed to be differences between 
healthy and sick individuals that give insight into how 
patients will react to drugs, which allows for tailored pre-
scriptions and dosages.
One of the most successful examples of the molecular 
biomarker approach is trastuzumab, also known as Herceptin 
(Genentech).2 The FDA approved trastuzumab for the treat-
ment of metastatic breast cancer in 1998 (Ignatiadis et al. 
2009), and it has been heralded as having a profound impact 
on the care of HER2+ breast cancers3 (Hudis 2007), and as 
“a major advance in targeted cancer therapies” (National 
Breast Cancer Coalition 2013). Trastuzumab is a human-
ized monoclonal antibody with two binding sites specific 
to the extracellular portion of HER2, a cell surface protein 
associated with the formation of homodimers as part of a 
cell growth signal pathway. When HER2 is overexpressed, 
the homodimers continually signal cells to grow and divide. 
1 Though precision medicine and personalized medicine are dif-
ferent projects, there is much overlap between the two and the term 
“precision medicine” is replacing the use of “personalized medicine” 
(Katsnelson 2013).
2 Imatinib (Gleevec), used to treat chronic myeloid leukemia (CML), 
is by far the most successful example of a targeted cancer therapy. 
However, CML is caused by a single chromosomal rearrangement, 
which means its causal dynamics are not widely applicable to other 
cancers.
3 Breast cancers are classified as HER2 + when there is an overex-
pression of the membrane-bound HER2 (Human Epidermal Growth 
Factor Receptor type 2) protein. HER2 + breast cancers comprise 
20–30% of invasive breast carcinomas, and these patients have 
decreased overall survival (Hudis 2007).
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Trastuzumab binds to the HER2 protein and blocks dimeri-
zation, which prevents further activation of signaling. Addi-
tionally, the antibody triggers the immune system to target 
HER2+ cells with increased antibody-dependent cell-medi-
ated cytotoxicity (Hudis 2007).
This example shows how the molecular biomarker frame-
work can work. Researchers identified a mechanism (a cell 
growth signaling pathway), which is causally relevant to car-
cinogenesis, and a specific biomarker (the HER2 protein) 
where a targeted intervention should substantially make a 
difference. Original clinical trials with HER2+ metastatic 
breast cancer patients showed positive results in 12–25% of 
the cases, depending on previous treatment regimes, thus 
providing a proof of principle for the effectiveness of tras-
tuzumab. In later trials, when administered in an adjuvant 
setting (i.e., trastuzumab plus chemotherapy), the risk of 
recurrence dropped by 40–50% and the risk of death dropped 
by one-third (Ignatiadis et al. 2009). In comparison to most 
cancer treatments, these results are impressive. However, 
given the straightforward nature of the intervention, greater 
response rates were expected. Additionally, further analy-
ses suggest that the chemotherapy accounts for much of the 
efficacy (Moja et al. 2012). Some anticipate that identifying 
more tumor characteristics (including more biomarkers) will 
lead to better efficacy (Ignatiadis et al. 2009). Others have 
suggested that the limited efficacy is due to misplaced atten-
tion on HER2 expression. That is, HER2 expression is a bad 
proxy for identifying which subpopulations will benefit from 
this drug. Michalis Karamouzis and colleagues (2007) sug-
gested that heregulin, a ligand that binds to multiple recep-
tors in the cell growth signal pathway just described, might 
be a better biomarker than HER2 overexpression.
The fact that trastuzumab was developed to treat invasive 
or metastatic cancers but is shown to be effective only in 
early stage cancers4 says something significant about the 
causality of cancer. The molecular biomarker approach 
might work if its target was part of a relatively static sys-
tem, but diseases like cancer are dynamic and progressive. 
Molecular biomarker approaches ignore the developmental 
nature of cancer in individuals, and of disease biology more 
generally. Disease-affected systems in individuals are com-
plex and have evolved robust and redundant pathways in 
order to address circumstances of disturbance. To investigate 
and understand these complex systems, multilevel and inte-
grated approaches are needed to account for causal dynamics 
involving feedback loops and robustness at different levels 
and across different timescales (Mitchell 2009). The molecu-
lar biomarker approach alone is insufficient.
Molecular Biomarkers as Difference Makers
In order to see why the molecular biomarker approach is 
insufficient, it is important to look at the causal framework 
employed. Recall that this approach involves finding the 
molecular differences between healthy and unhealthy indi-
viduals (or healthy and unhealthy tissues) and then interven-
ing on those differences to change the resulting phenotype. 
Thus, the molecular biomarker is what makes the difference 
between being healthy and unhealthy.
Many experiments designed to understand causal struc-
tures are modeled on methods following John Stuart Mill’s 
methods of difference: if you have two identical systems 
differing in only one factor, then differences in outcome can 
be attributed to that differing factor. Under these conditions, 
the factor is a “difference maker.” Knockout experiments 
are a widely used form of this causal reasoning strategy. For 
example, to infer the role of the gene TP53 in cancer, one 
can compare standardized mice, some with an inactivated 
form of TP53 and some with functioning TP53. If mice 
with inactivated TP53 show abnormal cell development that 
results in tumors, whereas mice with functioning TP53 show 
normal cell development, then—assuming all other factors 
are equal5—we can infer that the TP53 gene plays a causal 
role in cell development (Mitchell 2009).
Translational research, though, is not just about identi-
fying differences. Because the overall goal of translation 
is successful treatment, intervention resulting in a specific 
outcome is key. Thus researchers want to be able to identify 
the biomarker and then be able to change it such that the 
resulting phenotype is the desired one. James Woodward 
(2010) has an interventionist account of causation that for-
mally describes the casual framework of the molecular bio-
marker approach:
X causes Y if and only if there are background circum-
stances B such that if some (single) intervention that 
changes the value of X (and no other variable) were to 
occur in B, then Y or the probability distribution of Y 
would change. (p. 290)
This framework can be used in two ways: to identify 
causes and justify interventions. For the former, we can 
look back on the knockout experiment previously described. 
Using standardized mice is a way to achieve the same back-
ground circumstances (B). The variable X takes two val-
ues: functioning TP53 and inactivated TP53. The variable 
Y takes on two values as well: normal cell development and 
4 Trastuzumab is still used to treat metastatic HER2 + breast cancers 
but in combination with other therapies targeted at stopping HER2 
from forming dimers with other ligands (Baselga et al. 2012).
5 This is the reason to use standardized mice. These mice are inbred 
to be genetically identical and raised in the same environments. This 




abnormal cell development. This gives the following causal 
formulation: if one intervenes on TP53 and changes its value 
from functioning to inactivated, and the value of the normal 
cell development changes to abnormal, then one can infer 
that TP53 causes (i.e., makes a difference to) normal cell 
development.
Alternatively, we can start with statements about known 
causes such as “Inactivated TP53 causes abnormal cell 
development” and “Functioning TP53 causes normal cell 
development.” Then using Woodward’s framework, trans-
lational researchers should be able to say, “Given that func-
tioning TP53 causes normal cell development, with back-
ground circumstances B present, changing the value of TP53 
from inactivated to functioning will change the value of cell 
development from abnormal to normal.” Thus clinicians will 
be able to identify and justify where to intervene to get the 
result they want.
This example requires changing a gene, which is not the 
usual or desired approach. Ideally, researchers want to inter-
vene on components of pathways. To return to the trastu-
zumab example, we can consider X to have the values of 
homodimers present and absent, and Y has the values of 
cells growing and dividing or not. Thus, theory says that 
if they develop a protein that changes the value of X from 
homodimers present to absent, then Y will change from cells 
growing and dividing to not.
Despite the value of this causal framework, there are 
several limiting assumptions related to its application to 
cancer translational research.6 The first assumption is that 
there is a one-to-one relationship between the variant and 
the disease phenotype; i.e., “X causes Y,” not “X and Z cause 
Y” or “X causes Y and W.” Many-to-one relationships (“X 
and Z cause Y”), either as multiple pathways resulting in 
the same phenotype or many causal factors contributing 
to one phenotype, can make it difficult to know where to 
intervene because these cases facilitate redundancy in the 
system that, in some cases, compensates for the interven-
tion. Additionally, interventions on one-to-many or many-to-
many relationships (“X causes Y and W” or “X and Z cause 
Y and W”), such as genes showing pleiotropic effects in two 
or more seemingly unrelated pathways or phenotypes, can 
lead to unwanted outcomes (side effects). In other words, 
it is difficult to change X without affecting other variables. 
Thus, redundant pathways and pleiotropy will constrain the 
success of the difference-making causal framework used in 
the molecular biomarker approach. Even if the patient was 
prescribed two treatments (X causes Y and Z causes Y so 
treatment1 changes X to X* and treatment2 changes Z to Z*), 
changing the other value changes the background conditions 
so now the causal claims do not necessarily hold.
A second assumption is that the background conditions 
remain the same when you change the value of the variable 
(e.g., from functioning TP53 to inactivated TP53). That is, 
to test if functioning TP53 makes a difference on normal cell 
development, one needs a group of individuals with func-
tioning TP53 and a group of individuals with inactivated 
TP53. Additionally, for this causal framework to apply, the 
activation of TP53 has to be the only difference. This might 
be possible (or close to possible) in laboratory conditions 
with the use of standardized model organisms or cell cul-
tures, but in the clinical setting this assumption does not 
hold. The same mutation can be malignant in one individual 
but not in another depending on the genomic background or 
previous mutations (Greaves and Maley 2012). As well, this 
assumption makes it difficult to identify causal variables if 
the researchers are using clinical data rather than laboratory 
conditions. The variation from one individual to another 
often violates the assumption that the background condi-
tions are similar, and the partial effectiveness of trastuzumab 
in treating breast cancer illustrates this clearly.
Finally, this framework tends to treat all difference-
making factors symmetrically. That is, it assumes that all 
difference-makers in that system will affect the outcome in 
similar ways, such that there is no principled way to choose 
which factor(s) to privilege. Woodward (2010) suggests that 
knowledge of other characteristics of causal relationships, 
such as stability and specificity, will lead to more nuanced 
pictures of causal relationships, though the conditions for 
stability and specificity are less precisely characterized than 
those for difference-making. Interventions relevant to the 
clinical treatment of cancer (e.g., via surgery or chemother-
apy) require not only that a factor be identified as an actual 
difference-maker (versus a potential difference-maker); 
they also require detailed knowledge of how it makes a dif-
ference (e.g., how stable or specific the relationships are). 
Thus, identifying actual difference-makers permits the iden-
tification of multiple causes relevant to tumor progression 
or other aspects of cancer (Waters 2007), but it does not, on 
its own, suggest further characteristics that would facilitate 
successful clinical applications.
It is important to note that cancer researchers may or may 
not think that these three assumptions (there are one-to-one 
causal relationships, background conditions are sufficiently 
similar, and adequacy of difference-makers) are appropri-
ate or true of the world. The point is that they are assump-
tions of the causal framework used to identify molecular 
biomarkers. Regardless of whether researchers share each of 
the assumptions of the causal framework, they are embedded 
in the molecular biomarker approach. These methodological 
6 Note that what follows is not a critique of Woodward. He simply 
provides the formal language. Woodward is clear that this is a min-
imal model and not sufficient, and more substantial versions of the 
interventionist account can handle critiques similar to those I raise. 
I am arguing that this is the model that the biomarker approach 
requires.
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assumptions help to explain why this approach is insufficient 
to dissect cancer’s complex causal dynamics.
Evolutionary Biology Approach
Towards the end of the 20th century, a group of clinicians 
joined forces with a group of evolutionary biologists to 
reconnect medicine and evolutionary biology for what they 
termed Darwinian medicine. Although a driving aspect of 
this enterprise was the incorporation of evolutionary biology 
into medical school curricula (Williams and Nesse 1991; 
Nesse and Schiffman 2003; Nesse 2008; Nesse et al. 2010), 
the main research goals were to derive new insights into both 
medical and evolutionary questions, as well as to change 
clinical practices (Williams and Nesse 1991; Nesse 2001; 
Nesse and Stearns 2008; Stearns 2012; Valles 2012). The 
types of questions asked are: can an evolutionary perspec-
tive explain why particular symptoms appear? Why are cer-
tain individuals more susceptible to certain diseases? How 
should answers to the questions modify patient care? (Nesse 
2001; Nesse et al. 2006, 2010; Nesse and Stearns 2008).
Darwinian medicine has answered many medical ques-
tions utilizing population genetic theory and an adapta-
tionist research program (Nesse 2008; Nesse and Stearns 
2008; Valles 2012). An important example is explaining 
the prevalence of sickle cell anemia through heterozygote 
advantage. Individuals that are homozygous for the reces-
sive sickle cell allele (SS) suffer from sickle cell anemia, 
which is usually fatal due to the formation of blood clots 
and decreased oxygen delivery to tissues. Individuals that 
are homozygous for the dominant allele (AA) have normal 
red blood cells but are susceptible to malaria. Those that are 
heterozygous (AS) have both normal and sickled red blood 
cells, and have increased resistance to malaria, as the sickled 
phenotype makes the red blood cells less suitable for the 
malaria-causing parasite. In environments where malaria is 
epidemic (e.g., many regions of Africa), the AS genotype is 
more fit than either the AA or the SS genotypes. Therefore, 
under these environmental conditions, the S allele will be 
maintained in the population and thus sickle cell anemia will 
continue to persist. Note that this explains the persistence 
of sickle cell anemia but does not suggest any changes to 
clinical practices.
Antibiotic resistance, on the other hand, is a common 
example used to demonstrate medically relevant evolution 
in real time (Stearns 2012) and also has potential for clini-
cal application. Resistance was long thought to be a result 
of evolved coexistence with the host. But selection leads to 
higher virulence of pathogens, in part due to rapid parasite 
evolution (Williams and Nesse 1991; Nesse 2008; Nesse 
and Stearns 2008), and thus clinical efforts to minimize 
resistance were previously misinformed. By administer-
ing large doses of antibiotics to reduce the chance of de 
novo resistance mutations occurring, clinicians were actu-
ally selecting for rare resistance genes already present in the 
population, which could then be horizontally transferred to 
otherwise susceptible bacteria. This has led to more discus-
sions about the use of antibiotics in hospitals and clinics, 
including how to balance the killing of bacteria of an infec-
tion without strongly selecting for existing drug-resistant 
bacteria (Smith et al. 2015).
A key contrast between the molecular biomarker approach 
and the Darwinian medicine approach is that the former 
concerns individuals and the latter populations. However, 
the examples of sickle cell anemia and antibiotic resist-
ance show that the appropriate level at which to consider 
“the population” in evolutionary medicine can vary from 
populations of people (e.g., in the sickle cell anemia case) 
to populations of cells (or populations of microbes in the 
antibiotic resistance case). With respect to cancer, it is no 
different. For populations of people, mismatches between 
past and current environmental contexts can explain the per-
sistence of vulnerabilities to cancer (Greaves 2002; Aktipis 
and Nesse 2013). Additionally, population genetics can be 
applied to cancer incidence data to test hypotheses about the 
causal roles of mutation and drift in cancer (Frank 2007). 
This informs predictions about what factors are connected 
with shifts in incidence curves (measurements of how cancer 
occurrence varies with age), and thus when it is important to 
start screening for particular cancers in certain populations.
With respect to populations of cells, Peter Nowell pro-
posed a model of clonal evolution in tumors in which they 
develop over time through a series of stepwise somatic 
mutations followed by repeated selection (Nowell 1976). A 
mutation occurs in a somatic cell (either spontaneously or 
induced by a carcinogen) that gives it a growth advantage 
over neighboring cells and facilitates the clonal expansion 
of cells containing that mutation. As the population of cells 
expands, more mutations accumulate, some of which will 
give additional selective advantages, allowing those subpop-
ulations with the advantage to be selected for and to further 
expand. This process results in tumors that reflect specific 
and local environmental pressures. A more nuanced account 
of this process treats the tumor as a byproduct of the tissue 
ecosystem (Greaves and Maley 2012). Each time a treatment 
(e.g., chemotherapy) is given, it changes the ecosystem, 
which changes the development of the tumor. As a result, if 
part of the tumor is removed, then the tumor that recurs is a 
different tumor than what was originally there. This model 
illuminates why there is variation within a tumor and dif-
ferences between individuals with the same kind of cancer.
A primary goal of evolutionary medicine is to have clini-
cal impact. By analyzing incidence data from populations 
of people, we can develop screening policies. By applying 
evolutionary theory to populations of cells, new treatment 
regimens are suggested, such as adaptive therapy, where the 
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goal is to maintain tumors at a stable size rather than fully 
eliminate all cancer cells7 (Gatenby et al. 2009; Enriquez-
Navas et al. 2016). Cytotoxic drugs select for resistant cells 
and create an environment where the resistant cells can pro-
liferate, causing a tumor to become more aggressive and 
harder to treat. Thus, with adaptive therapy, tumor status 
is continually assessed and treatment plans are adjusted to 
achieve a desired tumor population such that chemosensi-
tive cells keep chemoresistant cells suppressed and limit 
their proliferation. That is, the dose of chemotherapy may 
increase, decrease, or not be administered at all, depending 
on the status of the tumor.
As with antibiotic resistance, investigating cancer through 
a Darwinian lens can lead to better uses of existing treat-
ments. However, this approach yields little mechanistic 
information that is relevant for the development of new treat-
ments (e.g., new drugs). More to the point, the approach 
does not help treat metastasis, the pathological form of 
cancer that is responsible for most deaths. The fact that a 
Darwinian medicine approach gives predictive power and 
thus offers preventive possibilities is incredibly important. 
Work done in this way suggests treating cancers early, pre-
sumably to never reach metastasis. However, not every case 
of cancer can be diagnosed early, nor should we necessarily 
depend on early detection and prevention (Narod et al. 2015; 
Prasad et al. 2015). Thus, we still lack effective approaches 
for the investigation and clinical treatment of cancer, espe-
cially metastatic cases. The Darwinian medicine approach 
alone is insufficient.
Natural Selection and Population‑Level Causes
As with the molecular biomarker approach, it is useful to 
look at the causal framework employed by the Darwinian 
medicine approach. Population genetics is the basis of Dar-
winian medicine (Nesse 2008; Nesse and Stearns 2008), 
which means natural selection, mutation, drift, and migra-
tion are key factors in its causal framework. However, in 
practice, Darwinian medicine prioritizes natural selection as 
a cause, making it an adaptationist program (Valles 2012). 
For example, its answer to why we are still vulnerable to 
certain diseases is that humans are “bundles of compromises 
shaped by natural selection… to maximize reproduction, not 
health” (Nesse and Stearns 2008, p. 28). That is, much of the 
research program focuses on maladaptations (Nesse 2005). 
Individual organisms in a population show heritable varia-
tion with fitness differences, but natural selection is a popu-
lation-level cause (see, e.g., Millstein 2006). Consequently, 
the causal framework of Darwinian medicine does not speak 
to the condition of specific individuals in the population.8
Notably, mutation, drift, and migration play more prom-
inent causal roles in evolutionary approaches to cancer 
than in traditional Darwinian medicine (Merlo et al. 2006; 
Aktipis and Nesse 2013). Because of this, I wish to separate 
evolutionary approaches to cancer from Darwinian medi-
cine, which has traditionally prioritized natural selection. 
Mutations create the heterogeneity in a tumor allowing for 
faster progression and therapeutic resistance (Merlo and 
Maley 2010; Park et al. 2010; Aktipis and Nesse 2013). 
Genetic drift occurs when population sizes are small. While 
tumors are generally large populations of cells, metastasis 
(the spread of cancer to other locations in the body) occurs 
via small clusters of cells that create population bottlenecks 
(Aceto et al. 2014). Additionally, cancer stem cell popula-
tions are usually composed of only a few cells (Baker et al. 
2014), which explains why deleterious mutations can go to 
fixation and why some tumors might be more aggressive 
than others. Migration plays several roles in cancer biology. 
One is related to mismatches between ancestral conditions 
and modern environments. For example, light-skinned indi-
viduals migrating towards the equator creates a mismatch 
between skin pigment and sun exposure, and thus changes 
their susceptibility to skin cancer (Aktipis and Nesse 2013). 
Migration might also be important in explaining metastasis, 
which inherently involves the migration of cells from one 
location to another. One model suggests that heterogeneity 
in a tumor selects for migratory cells (Chen et al. 2011).
Although these evolutionary insights into cancer com-
plement what has been discovered in terms of molecular 
mechanisms, they have not yet had a clinical impact. They 
account for why it is important to catch and treat cancers 
early, but do not give mechanistic information that would 
be useful for treating existing cancers in specific individu-
als. As a consequence, evolutionary approaches alone are 
insufficient for dissecting cancer’s complex causal dynamics.
8 It is important to be specific about what level one wishes to dis-
cuss individuals and populations. For example, as described earlier, 
one can apply evolutionary approaches to populations of cells or peo-
ple. Regardless of the level of organization, the Darwinian medicine 
approach cannot tell us about specific individuals within that popula-
tion (e.g., individual cells within a tumor or an individual patient in a 
certain population). It can, perhaps, tell us about a population of cells 
within a specific individual. Thank you to a reviewer for pointing this 
out.
7 Adaptive therapy is similar to metronomic therapy in that they 
both use low dose administration of drugs to reduce toxicity and 
slow tumor regression, as opposed to conventional high dose treat-
ment plans (Bocci et  al. 2008). However, where they differ is that 
metronomic therapies maintain a fixed schedule and adaptive ther-
apy requires assessing the tumor before making a treatment decision 
(Gatenby et al. 2009).
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Combining the Molecular Biomarker 
and Evolutionary Approaches?
Both the molecular biomarker and evolutionary medicine 
approaches give us important information about cancer 
biology, and so both approaches are necessary for making 
progress towards treating cancer. However, neither is suf-
ficient to dissect the causally complex dynamics of cancer, 
even when considered jointly. The approaches ask funda-
mentally different questions and therefore investigate causes 
using different frameworks. Researchers using the molecular 
biomarker approach want to know how cancers arise and 
progress in individuals, and how specific molecules make a 
difference to the outcome or phenotype. The identification 
of and dependence on biomarkers is a move to more closely 
connect the biology of the specific cancer to a treatment. 
Thus, it becomes more important for researchers to know 
the biological role certain biomarkers have in cancers to best 
develop effective treatment plans (Henry and Hayes 2012; 
Thariani et al. 2012). Alternatively, those using the evolu-
tionary biology approach want to know why cancers occur 
and progress, and why certain populations are more sus-
ceptible (Aktipis and Nesse 2013). The differences in how 
questions are formed between the biomarker and evolution-
ary biology approaches bear resemblance to Ernst Mayr’s 
proximate–ultimate distinction.
In a seminal paper, Mayr distinguished between two dif-
ferent kinds of biological causes: proximate and ultimate 
(Mayr 1961). Proximate causes are those studied by func-
tional biologists (e.g., physiologists and developmental biol-
ogists) and often answer “How?” questions. Explanations 
that come from this orientation involve immediate factors, 
such as day length or hormone levels. For example, a change 
in hormone levels causes an organism to change its behavior. 
In contrast, Mayr characterized ultimate causes as those that 
involve evolutionary history and are present due to many 
generations of natural selection. These explanations are his-
torical in nature and often answer “Why?” questions. For 
example, an organism has a behavior because it was benefi-
cial to its ancestors and was selected for within a population 
over many generations. In this 1961 paper, Mayr aimed to 
differentiate proximate and ultimate causes while arguing 
that both kinds of causes are necessary for a complete under-
standing of any biological phenomenon.
In cancer biology, the overexpression of the HER2 pro-
tein in breast cancers can be considered a proximate cause. 
That is, overexpression of HER2 causes the formation of 
homodimers which continually signal the cells to grow and 
divide, thus causing cancerous growth. On the other hand, 
one might suggest that because natural selection maximizes 
reproductive success and not health, women with early 
menarche are more susceptible to breast cancers (Aktipis 
and Nesse 2013). That is, selection for reproductive success 
is an ultimate cause of breast cancers. Thus, according to 
Mayr, the molecular biomarker and evolutionary biology 
approaches might together yield a complete causal frame-
work for understanding causation in cancer. Although having 
both approaches does give a fuller causal picture than just 
one approach alone, there are reasons why we might not 
want to interpret the biomarker and evolutionary biology 
approaches as separate or distinct in this way.
Laland and many of his colleagues have argued that the 
distinction between proximate and ultimate causes, though 
helpful at times (e.g., it prevents scientists from talking past 
each other, and allowed evolutionary biology and develop-
mental biology to independently grow and mature as dis-
ciplines), has actually hindered progress in evolutionary 
biology (Laland et al. 2011, 2012). This is because the dis-
tinction has become entrenched as a truth about the nature 
of causation, rather than as a heuristic in the study of causes 
(Laland et al. 2012). It has shifted from being a good way to 
approach causality in biological systems to being the only 
way one can understand causation in biological systems. 
The mentality has become entrenched because Mayr’s basic 
premise—proximate and ultimate causes answer different 
questions and are not in competition with one another—
implies that there is no reason to link them; proximate causa-
tion is not important to the investigation of ultimate causes 
and vice versa (Laland et al. 2012). This makes it difficult 
for the approaches to mutually inform one another in a way 
that would contribute to clinically relevant outcomes, where 
a more complete picture of the causal landscape is necessary. 
This mentality appears to be manifested in cancer research, 
where the two approaches are funded through different ave-
nues and the research communities minimally overlap.9
Maintaining the proximate–ultimate distinction leads 
to other problems as well. First, Laland et al. (2011, 2012) 
argue that this distinction cannot account for cases of recip-
rocal causation. If developmental processes are interpreted 
as proximate causes and separated from evolutionary pro-
cesses (ultimate causes), we miss the fact that developmental 
processes contribute to the phenotypes on which selection 
acts, and these mechanisms are under selection themselves. 
Thus, developmental processes (proximate causes) are both 
an input and an output of ultimate causes (e.g., selection). 
Second, the proximate–ultimate distinction and how-why 
distinction are false dichotomies because it is possible to 
ask questions that can be answered with both or neither cate-
gory (Calcott 2013). Calcott also points out that considering 
9 Organizations like the US National Cancer Institute, the main 
source of funding for the biomarker approach, are starting to fund 
more evolutionary approaches. However, the budget for the latter 




ultimate questions to be historical explanations can be con-
fusing, as it is not clear what it means for an explanation to 
be historical. This affects the range of possible answers to 
questions regarding ultimate causes and indicates that we are 
getting only partial answers or explanations.
While these are legitimate concerns, these and other cri-
tiques of the proximate–ultimate distinction came mostly 
from those working on general evolutionary questions (not 
those bringing evolutionary approaches to cancer). Evo-
lutionary biologists have been concerned with whether 
evolutionary theory needs to be extended to include devel-
opmental factors and other causes typically categorized as 
proximate (Laland et al. 2014). But little to no critique of 
the distinction has come from developmental biologists. Do 
studies typically categorized as proximate causation (such 
as developmental biology) need to consider studies typically 
categorized as ultimate causation (such as evolutionary biol-
ogy)? This is a more applicable question in the context of 
cancer translational research, where much of the research 
would be categorized as proximate.
The molecular biomarker approach is predominant (by the 
amount of money allocated, number of research programs, 
papers, etc.) in the methodologies of developmental biology. 
Although discovering molecular mechanisms is essential for 
knowing where to intervene on individuals with cancer, an 
evolutionary perspective is currently most helpful for devel-
oping public health initiatives for communities and popu-
lations. That is, an evolutionary perspective helps inform 
when to start screening and assessing individuals within a 
population.10 But simply identifying or acknowledging the 
proximate–ultimate distinction does not facilitate bringing 
together the causal frameworks of the two approaches. The 
approaches are complementary to each other, but just having 
both side-by-side is not enough. That is, there are probably 
important factors or dynamics that are being missed (e.g., 
reciprocal causation) by not using a framework that consid-
ers proximate and ultimate causation together. The standard 
molecular biomarker and evolutionary biology approaches 
do not fully capture the complex causal structure, even when 
considered jointly. We need a perspective on causation that 
integrates both developmental and evolutionary approaches 
to cancer in order to better understand cancer and identify 
effective clinical treatments.
Overcoming the Proximate–Ultimate 
Distinction Through Evolutionary 
Developmental Biology
Integrating proximate and ultimate causal frameworks is not 
a trivial task; proximate and ultimate causes are typically 
studied using different methodologies, work on different 
timescales, and depend on different underlying conceptual 
foundations. Similar to cancer translational research, evolu-
tionary developmental biology (EvoDevo) aims to explore 
the connections between the development of individual 
organisms and their evolutionary transformation to discover 
causal-mechanistic explanations of individual traits involved 
in population-level events (Laubichler 2007; Hamilton 
2009). Thus I propose turning to EvoDevo for assistance 
in integrating proximate and ultimate causal frameworks.
EvoDevo can be considered to have two research axes: 
(1) the evolution of development, or how developmen-
tal processes and programs change over time; and (2) the 
developmental basis of evolution, or how developmental 
processes and properties affect evolutionary trajectories 
(Müller 2007; Love 2015). These axes are sometimes sepa-
rated into “EvoDevo” and “DevoEvo,” respectively (Hall 
2000; Gilbert 2003), but here I will consider them together 
as “EvoDevo.” The discipline of EvoDevo is heterogenous 
in its methods and questions, pulling from evolution, devel-
opment, molecular biology, paleontology, and many other 
disciplines (Müller 2008; Love 2015), and uses key concepts 
to orient research problems and questions. These concepts 
include, among others, novelty, modularity, and evolvability 
(Arthur 2002; Müller 2007; Love 2015).
Though the goals of EvoDevo and cancer translational 
research are slightly different (namely explanation versus 
intervention), they have similar desires—integration of 
population- and individual-level causes, causal-mechanistic 
explanations of population level events, and understanding 
how knowledge of individuals and populations inform one 
another. We can also see how cancer biology can map onto 
EvoDevo’s research axes: cancer is complex with devel-
opmental features evolving over the lifetime of the cancer 
(EvoDevo), and cancer systems have variation in relevant 
properties that facilitate change in certain directions (Devo-
Evo). Thus I suggest cancer translational research follow 
EvoDevo’s lead and explore how attending to the conceptual 
issues can help orient research programs.
Cancer researchers do sometimes invoke evolutionary 
developmental biology but it is often when evolution and 
development are known to be involved (Kumar et al. 2017) 
or making use of discovered biology such as details pertain-
ing to certain signaling pathways (Alekseenko et al. 2018). 
The leaders of EvoDevo have identified cancer as a place 
where EvoDevo could be helpful in the future, but, again, 
10 Those using an evolutionary approach to cancer want to be able to 
inform treatments and interventions on individuals but are currently 
not able to. Their success is currently in informing public health ini-
tiatives regarding screening practices.
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they make use of the progress in biological discovery by 
connecting cancer with important developmental pathways 
and stem cells (Moczek et al. 2015). The use of EvoDevo’s 
approach and conceptual issues remains untouched but 
potentially powerful. Here I will apply a notion of modular-
ity and then a related concept of evolvability. In both cases, 
I will discuss how the concept is used in EvoDevo and then 
how it could be applied to cancer translational research. I use 
modularity to show how it is not just the general concept that 
I find helpful for cancer translational research, but specifi-
cally the application of EvoDevo’s version of modularity. 
The discussion applying evolvability to cancer research is 
briefer as it is the concept itself that I apply rather than the 
history of the concept as well.
Modules and Modularity in EvoDevo
One way EvoDevo has integrated evolution and develop-
ment is through the notion of modularity (von Dassow and 
Munro 1999). There are many definitions of modularity but 
a module is generally understood to be an entity or part that 
is discrete or autonomous in some ways but also integrated 
within a larger whole (usually the rest of the organism) in 
other ways (Wagner et al. 2007). Modules can be processes 
or structures (Raff 1996), and be instantiated at any hierar-
chical level. For example, fragments of cis-regulatory DNA 
(Arnone and Davidson 1997), morphogenic fields, signal 
transduction pathways, gene regulatory networks (Gilbert 
and Bolker 2001), and leaf primordia (Gass and Bolker 
2003) can all be modules. Furthermore, organisms them-
selves can be considered modules of higher-level individu-
als, such as superorganisms (Schlosser and Wagner 2004). 
Thus, modules can be embedded in higher-order modules 
(Schlosser 2004).
Modularity involves part-whole relationships, but evolu-
tionary biologists and developmental biologists have thought 
about those relationships differently. Evolutionary biologists 
consider modules to be dissociable subunits or parts of a 
larger system, typically the adult organism (Gass and Bolker 
2003). Evolutionary modules are parts autonomous enough 
to change without appreciably changing other aspects of the 
organism. Rasmus Winther (2005) calls this a partitioning 
strategy, where you can understand the whole as a sum of 
the parts. On the other hand, developmental biologists refer 
to modules as collectives of entities and processes that act 
in some unified way to perform a function (Bolker 2000). In 
this view, a strategy of articulation is used when the relation-
ship or interactions between parts is just as important, if not 
more, than the parts themselves (Winther 2005). In sum, for 
evolutionary approaches, the autonomy of a module is usu-
ally foregrounded, whereas in developmental approaches, 
the interactivity or integration between modules is more 
important.
Regardless of whether autonomy or integration is fore-
grounded, biologists still recognize that invoking modules 
and modularity requires being concerned with both auton-
omy and integration. One way that EvoDevo combines the 
evolutionary and developmental approaches to modules is 
that evolutionary modules are the phenotypes that result 
from particular developmental modules (Gass and Bolker 
2003). However, there is not a one-to-one relationship 
between developmental modules and resulting evolutionary 
modules (Bolker 2000; Schlosser and Wagner 2004); mul-
tiple modules of the same type can be used in a single path-
way or process, or modules can overlap by sharing elements 
(Schlosser 2004). Thus, what is critical for these EvoDevo 
researchers in bridging the developmental and evolutionary 
approaches is how modules are individuated and interact 
with one another. Once meaningful modules are identified, 
the interactions between them become the focus because it 
is the changes in interactions that result in phenotypic dif-
ferences and therefore evolutionary change.11
This EvoDevo approach to modularity combines evo-
lutionary and developmental approaches to modules and 
modularity in a particular way (evolutionary modules are 
the products of developmental modules). By doing this, the 
EvoDevo researchers shift attention away from proximate 
and ultimate causation because they can no longer consider 
the proximate causes (developmental modules) separately 
from the ultimate causes (the variation linked to evolution-
ary modules). Though EvoDevo is concerned with the iden-
tification of modules (as are evolutionary biologists) and 
how they interact with each other (similar to developmental 
biologists), it is the changes in interactions over time that 
get foregrounded for EvoDevo because it is those changes 
that lead to evolutionary change and population-level events.
Using this version of modularity (where the focus is on 
changes in interactions over time) as a way to integrate dif-
ferent causal frameworks forces us to shift our attention in 
two main ways. First, as noted, we shift our attention away 
from investigative strategies that are specific to proximate 
or ultimate causation, and thereby avoid treating proximate 
and ultimate causation separately. Second, as I will discuss 
below, a causal perspective based on this version of modu-
larity inherently requires the consideration of relationships 
between multiple levels of organization and across different 
timescales (e.g., developmental and evolutionary). Consid-
eration of multiple levels and different timescales is not new, 
11 The agnathan-to-gnathostome transition is a good example of 
this, where heterotopic (spatial) changes in developmental modules 
resulted in the gnathostome-type oral apparatus in which both the 
upper and lower jaws are derived from the mandibular arch. This is in 
contrast to the agnathans where only the lower lip is derived from the 




but adopting this modularity-based perspective provides a 
rationale for focusing on the changes in interactions between 
the levels and specifically across time. Thus, a modularity-
based causal perspective is one that focuses on the changes 
in levels of integration of an identified part (module) with 
respect to other parts (including the organism as a whole) 
and how those changes affect the system of interest over 
time.
Modules and Modularity in Cancer Translational 
Research
The EvoDevo interpretation of modularity presented here 
was not meant to replace the evolutionary or developmental 
interpretations with an intermediate notion but rather inte-
grate parts of each interpretation to allow for the discussion 
of multiple levels and timescales. Similarly, with cancer 
I do not aim to necessarily replace the biomarker or evo-
lutionary approaches to cancer translational research, but 
rather provide a framework for interpreting more complex 
accounts of causation. Without the modularity framework, 
investigations usually concerned either the individual (for 
the biomarker approach) or populations (for the evolutionary 
approach). With a modularity framework in place, we can 
identify many potential modules in cancer—various molecu-
lar pathways, cells, tumors, tissues, the circulatory system, 
and/or the immune system, for example. Which modules 
are meaningful depends on the questions being asked or the 
phenomena of interest. Because the emphasis is on changes 
in interactions between modules, no level or system is prior-
itized but discussions of causal importance are still possible 
because the same structure for understanding causes holds 
across levels.
For clarity, let’s consider a generic cancer as it progresses 
from tumorigenesis to metastasis. At various times, differ-
ent parts (modules) become the focus and sometimes the 
success of the cancer depends on increased interactions and 
sometimes decreased interactions. Cells normally interact in 
specific and controlled ways to form tissues, but a cell can 
become cancerous when it gains enough autonomy (i.e., it 
becomes highly modular) to defect from or cheat within the 
tissue. As that cell reproduces and grows into a tumor, it 
progressively loses some autonomy and becomes integrated 
with its descendent cells in the tumor. As the tumor contin-
ues to grow, nutrient and waste transport become important 
and its dependence on angiogenesis (the development of new 
blood vessels) and interactivity with the circulatory system 
increases. For the cancer to spread (metastasize), cells use 
the circulatory system to get to a new location. Once in a 
distant tissue, it must integrate into the tissue to evade the 
immune system. Additionally, when treatment is adminis-
tered (especially immunotherapy), the cancer forms a differ-
ent, complex iterative relationship with the immune system.
The interactions between modules and the relation-
ships between the parts and whole are constantly chang-
ing depending on the tumor microenvironment, as long as 
the cancer exists. These multilevel changes in relationships 
across different timescales facilitate and constrain the evolu-
tion of the cancer in certain ways, thus affecting any possi-
ble cancer-related treatments. For example, if the increased 
dependence on the circulatory system is necessary for the 
evolution of the tumor, then decreasing or preventing the 
integration with the circulatory system would constrain the 
cancer’s ability to develop and evolve. Likewise, if the can-
cer’s survival is dependent on autonomy from the immune 
system, being able to decrease the cancer’s autonomy will 
be beneficial for the patient.
What this framework shows is that it is not necessar-
ily better for modules to have higher degrees of autonomy 
or integration. It is sometimes assumed higher degrees of 
autonomy are beneficial as that allows independent parts 
to vary without affecting the function of other parts. But 
what the above example shows is that in some situations it 
will be beneficial for there to be high degrees of autonomy 
(e.g., beginning stages of tumorigenesis) and some situations 
where it will be beneficial to be integrated (e.g., colonizing 
distant tissues). And, of course, which is better will depend 
on which point of view gains the benefits (the host/patient 
or the cancer).
Additionally, knowing which parts of the organism to 
consider as meaningful parts and wholes (i.e., what should 
be studied) is only possible if cancer is considered in its tem-
poral aspect. Different modules become important during 
different stages of cancer progression. During tumorigenesis, 
the meaningful part might be the cell and the meaningful 
whole might be the tissue in which that cell resides. And 
the question to ask relates to what changed such that the cell 
was able to become more autonomous within that tissue. The 
answer could be molecular, ecological, environmental, or 
some combination. Later in tumor growth, one might want to 
focus on the relationships between the tumor and the circula-
tory system. How and why is angiogenesis induced? How 
do those changes affect the evolutionary trajectory of the 
cancer? Furthermore, during metastasis, it will be impor-
tant to investigate the relationships between the clusters of 
cells that are shed from the tumor, the circulatory system 
through which they travel, the immune system which they 
must evade, and the new tissues which they ultimately must 
colonize. How do some cells evade the immune system 
while others cannot? Why is a cluster of cells more suc-
cessful at metastasis than single cells? How do metastases 
succeed in the new tissues such that they integrate enough 
to evade the immune system but stay autonomous enough 
to remain cancerous?
The shift the modularity frameworks brings is shifting 
from identifying that cells are able to defect from and cheat 
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within a tissue to understanding how those cells are able 
to. Cells defect and cheat more often than cancers arise, so 
what are the differences between defections when cancers 
arise and when they do not? As well, millions of cancer 
cells circulate throughout the circulatory system but never 
manifest in disease (Massagué and Obenauf 2016). What 
are the differences between the circulating tumor cells that 
eventually die and those that will successfully survive to 
form metastases?
Tracking multilevel causal interactions through the pro-
gression of cancer has the potential to open up novel clinical 
treatment options that were previously hidden in the divide 
between proximate and ultimate causation. For example, 
immunotherapy appears to bridge proximate and ultimate 
perspectives by striving for the precision of the biomarker 
approach but also taking advantage of the evolving immune 
system to combat evolving cancerous systems. Research-
ers want to find proteins that are over-expressed in all and 
only cancer cells (such as PD-L1; Iwai et al. 2002) across 
all time points so that the immune system can continue to 
target and kill the cancer cells regardless of how the cancer 
evolves or its state of progression. However, if we apply 
what I have discussed here regarding the complexity of mul-
tilevel causal interactions across time, we can see there is 
still much more work to be done in order to predict and 
manage the side effects (e.g., autoimmune disorders) and 
potential complications or failures of immunotherapies 
(especially regarding metastasis and recurrent tumors). That 
is, treatments that make use of both proximate and ultimate 
causal frameworks still fail to predict complications of the 
treatment. This modularity perspective automatically sug-
gests that changing the relationship (interactions) between 
the cancer and the immune system will affect the evolution 
of the cancer as well as the relationship between the immune 
system and the patient (i.e., increased chances of developing 
autoimmune disorders). Knowing what else each module of 
interest interacts with can point researchers towards potential 
complications as changing one interaction (e.g., increasing 
the interactions between the cancer and the immune sys-
tem) is likely to also change other interactions (such as the 
interaction between the immune system and other parts of 
the patient).12
As this example shows, identifying differences (i.e., the 
framework used in the biomarker approach) alone is not 
problematic. In fact, it is necessary. What are the differences 
that allow for some cheating cells to become cancerous and 
others to die? These differences make for potential places 
of intervention. The modularity framework reminds us that 
these differences need to be fully interpreted and that causes 
involve multiple integrated levels that need to be taken into 
consideration.
Evolvability in EvoDevo
Evolvability was not a concept of concern to developmen-
tal biology or much of evolutionary biology (particularly 
population genetics) but has, at times, been considered a 
central concept of EvoDevo (Hendrikse et al. 2007; Minelli 
2009). Like modularity, evolvability has many definitions. 
We can consider the study of evolvability as the study of 
what facilitates evolutionary change (Love 2015). More spe-
cifically, evolvability is defined as “an organism’s capacity 
to generate heritable phenotypic variation” (Kirschner and 
Gerhart 1998, p. 8420), or “the capacity of a developmental 
system to evolve” (Hendrikse et al. 2007, p. 394). Despite 
slight differences in what level generates the variation or 
evolves, what is important here is the ability to generate 
heritable variation.
Evolvability and modularity are related, as it is often con-
sidered that high degrees of modularity are required for the 
evolution of complex phenotypes. But evolvability includes 
other characteristics besides modularity or autonomy. Marc 
Kirschner and John Gerhart have identified multiple prop-
erties of evolvable systems (i.e., systems that facilitate the 
generation of heritable variation; Gerhart and Kirschner 
2003). The most well-known include compartmentation or 
modularity, weak regulatory linkage, and exploratory behav-
ior (for more properties see Kirschner and Gerhart 1998). 
Each of these properties (including those not discussed here) 
reduces dependence on other parts while providing robust-
ness and flexibility.
Evolvability in Cancer Translational Research
Evolvability is often studied at the molecular and develop-
mental levels so it seems to be a promising way to integrate 
the molecular biomarker and evolutionary approaches. As 
well, genetic variation is known to be associated with faster 
progression, aggressiveness, and persistence of cancers 
(Maley et al. 2006; Park et al. 2010). Thus, understanding 
and identifying properties that facilitate the generation of 
variation will be important to the development of successful 
treatments and other clinical applications.
Treatments that use evolutionary theory are often 
changes in the dosing regimen or treating the microenvi-
ronment rather than the cells themselves (Gatenby et al. 
2009; Enriquez-Navas et al. 2016). These approaches aim 
to manage the cancer rather than fully eliminate it. Some 
researchers have asked, though: What if we could target 
the evolvability instead? What are the characteristics of 
12 The relationship between the immune system and the patient is 
incredibly integrated. Thus, even if the interaction relationship under 
investigation is between the cancer and the immune system, it should 
not be surprising that changing that relationship is also going to 
change the patient’s relationship with their immune system.
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evolvable systems and can we target them? (Rosenberg and 
Queitsch 2014; Fitzgerald and Rosenberg 2017). Essentially 
the project is to target the drivers of evolution, rather than 
the products.
Genetic variation is usually thought to be the product of 
genetic instability due to mutations in DNA repair mecha-
nisms or chromosomal rearrangement. A recent study has 
shown that, across various cell lines and samples, TGF-beta 
(transforming growth factor-beta) signaling downregulates 
DNA repair, which leads to genetically diverse populations. 
Additionally, exposure to TGF-beta seems to be connected 
to chemotherapy resistance and (thus) increased adaptability 
(Fitzgerald and Rosenberg 2017; Pal et al. 2017).
Whether the acquired resistance to chemotherapy actu-
ally results in more dangerous cells or cancer is still an open 
and empirical question but theory suggests that exposure to 
TGF-beta is causally associated with cancer progression and 
persistence. Can we target parts of the TGF-beta signaling 
pathway as a way of slowing evolutionary processes present 
in cancer progression? There are already clinical trials that 
target this pathway (Herbertz et al. 2015) but how successful 
these treatments are also depends on what other processes 
TGF-beta signaling is involved in. Aspects of wound heal-
ing, immune responses, and embryo development use TGF-
beta signaling (Fitzgerald and Rosenberg 2017; Pal et al. 
2017), reminding us that processes and systems are inter-
connected and have complex relationships. Thus, we might 
not want to fully knock down TGF-beta, as having genetic 
diversity is key for the success of other processes vital to 
healthy adult life. More work is needed to understand under 
what circumstances targeting evolvability would be benefi-
cial with respect to treating the cancer, while minimizing 
side effects.
Again, this example shows that the identification of bio-
markers is not problematic. This, and other studies, have 
identified TGF-beta as upregulated in cancer cells, thus mak-
ing it a biomarker. However, its presence is reinterpreted 
within the evolutionary framework. This reinterpretation 
suggests criteria for why we might think targeting certain 
molecules or proteins might be more successful than others.
Conclusion
The molecular biomarker and evolutionary biology 
approaches to cancer translational research use widely 
accepted methods of investigation and explanation in biol-
ogy and biomedical research. These approaches lend them-
selves well to the current scientific culture as they produce 
quick results for publications and grants, and ultimately give 
simple and clean explanations that are easy to understand 
and convey to others, including the general public. How-
ever, they only occasionally produce or lead to “successful” 
interventions. Additionally, these interventions only help a 
small percentage of the population (see the Herceptin dis-
cussion above), or are far from clinical implementation (e.g., 
adaptive therapy).13 Therefore, following Mayr’s suggestion 
to maintain separate proximate and ultimate causal frame-
works does not work for cancer translational research, nor is 
it necessarily better than having just proximate or just ulti-
mate causal frameworks. This is because cancer translational 
research requires more than explanation and understanding. 
For example, knowing that you were more susceptible to 
a certain kind of cancer because of an upregulated path-
way that gives those cells a fitness advantage does not tell 
one where to intervene in order to prevent or eliminate the 
cancer. In other words, the evolutionary biology population 
approach does not isolate difference makers in such a way 
that is useful for treating patients. Furthermore, oncologists 
and society alike would prefer interventions that work with-
out first almost killing the patient (in theory, enough radia-
tion or chemotherapy would kill all of the cancer cells, but 
the number of healthy cells also killed is far greater than 
zero). If the goal is effective and relatively safe interven-
tions, we need a framework that embraces the causal com-
plexity of cancer biology and transforms proximate and ulti-
mate investigative strategies into a single, more cohesive 
perspective.14
In this article, I proposed a novel perspective on cau-
sation in cancer through evolutionary developmental biol-
ogy. I argued that the standard research programs map onto 
Ernst Mayr’s proximate–ultimate distinction, but that in the 
context of cancer translational research, this distinction can 
be overcome with the help of evolutionary developmental 
biology’s strategy to integrate proximate (developmental) 
and ultimate (evolutionary) causes. I first used a version of 
modularity that shifts the attention away from individual 
modules to changes in interactions between modules over 
time. I suggested that identifying which and how interactions 
13 Adaptive therapy has been used in small pilot clinical trials for 
treatment of prostate cancer (e.g., clinical trial NCT02415621; Zhang 
et al. 2017).
14 There are other proposals to overcome the limitations of the bio-
marker approach. For example, Dumitru Iacobas has proposed a 
Genomic Fabric Perspective (e.g., Iacobas 2016) that compares tran-
scriptomes of networks within individuals across time. This gives 
a dynamic perspective of integrated networks, which gets at some 
properties discussed related to modularity. However, it is unclear 
how this perspective translates into the clinic (I suspect there are at 
least limitations related to data storage and analysis). I restricted the 
perspectives discussed here to those that are more widespread and 
obviously discuss translational goals. I am also ready to accept that 
multiple frameworks and perspectives might be useful within cancer 
translational research given the heterogeneity of cancer (i.e., some 
approaches work better for some cancers). My proposed approach is 
just one suggestion that would need to be empirically tested (along 
with other proposed approaches).
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change when, for example, cells switch from being non-can-
cerous to cancerous could be potential points of intervention. 
I then used the concept of evolvability as a way to integrate 
cancer translational research’s molecular biomarker and 
evolutionary approaches. Using an evolvability lens to rein-
terpret identified biomarkers that differentiate the healthy 
from unhealthy helps determine which proteins or molecules 
might be the best targets. It has been suggested that targeting 
the properties that drive the generation of variation will be 
more successful than targeting the products of that variation.
Both of the current predominant approaches suggest 
that catching and treating cancers early is the best option.15 
Though shown to be effective in some cases, this is not 
always possible, nor is it always the best option (see, e.g., 
Narod et  al. 2015; Prasad et  al. 2015). Therefore, it is 
essential to develop treatment regimens for advanced and 
metastatic cancers. The EvoDevo-based causal perspective 
described here is one way forward for a research program 
in cancer translational research that does not deny the vast 
amounts of existing data, but provides a path to discover and 
interpret these results more effectively than had previously 
been done. In addition, this perspective promises to foster 
research into novel clinical applications.
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